The value of [18F]PSMA-1007 PET/CT combined with mpMRI in diagnosing prostate cancer with PI-RADS 3–4 lesions

Runjie Shui, Jihui Li, Shushan Ge, Jinming Cao, Shengming Deng, Bin Zhang · 2026

Read The value of [18F]PSMA-1007 PET/CT combined with mpMRI in diagnosing prostate cancer with PI-RADS 3–4 lesions by Runjie Shui, Jihui Li, Shushan Ge, Jinming Cao, Shengming Deng, Bin Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350630.txt.

Description

Runjie Shui and co-authors tested in 2026 whether PSMA PET/CT joined with multiparametric MRI lifts prostate cancer diagnosis. The focus was intermediate PI-RADS 3 to 4 lesions. There, benign and malignant disease are hardest to split. True sorting avoids needless biopsies. It also catches cancers that need treatment.

One hundred thirty-five patients scanned from early 2024 to late 2025 were studied in look-back. Fluorine-18 PSMA-1007 PET/CT was weighed against MRI. Age, antigen measures, prostate volume, and scan uptake values fed a multi-parameter model. The joined path beat either mode alone for spotting cancer in this murky group. The model gives a step toward fewer missed cancers and fewer needless biopsies.

Catalog record

CREATORRunjie Shui, Jihui Li, Shushan Ge, Jinming Cao, Shengming Deng, Bin Zhang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13350630

Browse the full library · About the Tower of Babel